266 related articles for article (PubMed ID: 33680942)
1. The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer.
Zhai C; Zhang X; Ren L; You L; Pan Q; Pan H; Han W
Front Oncol; 2020; 10():619010. PubMed ID: 33680942
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study.
Jiang HT; Li W; Zhang B; Gong Q; Qie HL
Int J Gen Med; 2021; 14():7625-7637. PubMed ID: 34754233
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
Front Oncol; 2021; 11():628124. PubMed ID: 33791214
[TBL] [Abstract][Full Text] [Related]
4. Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-small cell lung cancer: a retrospective cohort study.
Dai YJ; Qiu YR; Lin JG; Dai YB; Su YX; Yamada T; Uematsu S; Xu TW
J Thorac Dis; 2023 Oct; 15(10):5680-5688. PubMed ID: 37969289
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety analysis of anlotinib combined with PD-1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study.
Ye X; Huang A; Zhou Y; Kuang Y; Wang W; Gu A; Xu L
J Thorac Dis; 2023 Apr; 15(4):2003-2011. PubMed ID: 37197506
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.
Xiang M; Yang X; Ren S; Du H; Geng L; Yuan L; Wen Y; Lin B; Li J; Zhang Y; Feng G; Du X
Oncologist; 2021 Dec; 26(12):e2130-e2135. PubMed ID: 34423518
[TBL] [Abstract][Full Text] [Related]
7. A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer.
Wang HY; Chu JF; Zhao Y; Tang H; Wang LL; Zhou MQ; Yan Z; Liu YY; Yao ZH
Cancer Manag Res; 2020; 12():3827-3834. PubMed ID: 32547218
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study.
Chu T; Zhang W; Zhang B; Zhong R; Zhang X; Gu A; Shi C; Wang H; Xiong L; Lu J; Qian J; Zhang Y; Dong Y; Teng J; Gao Z; Wang W; Shen Y; Nie W; Lim JU; Mehta HJ; Neal JW; Lou Y; Xu J; Zhong H; Han B
Transl Lung Cancer Res; 2022 Jul; 11(7):1394-1404. PubMed ID: 35958322
[TBL] [Abstract][Full Text] [Related]
9. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
Gao X; Peng L; Zhang L; Huang K; Yi C; Li B; Meng X; Li J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2661-2671. PubMed ID: 34748028
[TBL] [Abstract][Full Text] [Related]
10. Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.
Nie C; He Y; Lv H; Gao M; Gao X; Chen B; Xu W; Wang J; Liu Y; Zhao J; Chen X
Front Oncol; 2022; 12():885350. PubMed ID: 35860585
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study.
Hu WX; Peng JC; Wang Y; Jin H; Geng N
Int J Gen Med; 2022; 15():4453-4464. PubMed ID: 35509604
[TBL] [Abstract][Full Text] [Related]
12. A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors.
Li SH; Li YW; Li YJ; Liu LB; Zhang Q; Lu D
Int J Gen Med; 2023; 16():4485-4498. PubMed ID: 37814643
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study.
Dou XJ; Ma RY; Ren DW; Liu Q; Yan P
Lung Cancer (Auckl); 2024; 15():29-40. PubMed ID: 38560413
[TBL] [Abstract][Full Text] [Related]
14. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
[TBL] [Abstract][Full Text] [Related]
15. A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer.
Shao Y; Luo Z; Yu Y; He Y; Liu C; Chen Q; Zhu F; Nie B; Liu H
Front Oncol; 2022; 12():939343. PubMed ID: 35965587
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab.
Jiang F; Li J; Kong X; Sun P; Qu H
Front Pharmacol; 2022; 13():973448. PubMed ID: 36238567
[No Abstract] [Full Text] [Related]
17. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
[TBL] [Abstract][Full Text] [Related]
18. Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Xiong Q; Qin B; Xin L; Yang B; Song Q; Wang Y; Zhang S; Hu Y
Front Oncol; 2021; 11():659380. PubMed ID: 34395243
[TBL] [Abstract][Full Text] [Related]
19. Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment.
Yu C; Jiang L; Yang D; Dong X; Yu R; Yu H
Onco Targets Ther; 2022; 15():1221-1228. PubMed ID: 36262804
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study.
Sun L; Zhao Q; Wang Y; Wang Y; Zheng M; Ding X; Miao L
Int J Gen Med; 2023; 16():4165-4179. PubMed ID: 37720175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
